셀트리온

068270KOSPI기초 의약물질 제조업

58.9 / 100

Reference Date: 2026-04-13

Financial Score22.5 / 40

News Sentiment14.4 / 25

Momentum10.0 / 20

Disclosure12.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Slightly down 2.8% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Celltrion is a global biotech company specializing in developing and commercializing biopharmaceuticals for autoimmune diseases and oncology, with 11 globally approved biosimilar products, including its first biosimilar, Remsima (CT-P13). It has expanded its global presence through strong market dominance in Europe and the U.S., and secured FDA approval for its subcutaneous infliximab formulation in 2023, aiming for 41.625 trillion KRW in sales by 2025.

Number of Employees

3,153people

Average Salary

108.2M KRW

Score Calculation Basis

Detailed Financial Score

PER

42.78Industry Average 33.453.0Point

Higher than industry avg (caution)

PBR

2.66Industry Average 2.032.5Point

Higher than industry avg (caution)

ROE

5.91Industry Average -4.293.5Point

Well below industry avg

Debt Ratio

3.05Industry Average 6.616.5Point

Half of industry avg (excellent)

Trend 2023~20257.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲40.4% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲56.5% (2-year basis)

ROE Trend

1.0 / 4

Avg ROE 4.5% (improving, 3yr)

Detailed News Sentiment

53 totalPositive 16Neutral 31Negative 1Average Sentiment Score 58.2

Detailed Momentum

52-week position5.0Point

52w mid range (52%)

Current 199,700Won52-week high 248,50052-week low 146,215

1-month return2.0Point

1m -2.82% (slight drop)

Volume trend3.0Point

Volume flat

Detailed Disclosure

16 totalPositive 1Neutral 15Negative 0

Neutral투자판단관련주요경영사항 (CTP51(키트루다 바이오시밀러) 한국 임상 3상 시험계획 변경신청)2026-03-30
Neutral투자판단관련주요경영사항 (마이크로바이옴 장질환 신약 후보물질 Licensein 계약 체결)2026-03-25
Neutral장래사업ㆍ경영계획(공정공시)2026-03-24
Neutral신규시설투자등2026-03-24
Neutral기업가치제고계획(자율공시)2026-03-24